45 results
6-K
EX-1
BLRX
Bioline Rx Ltd
17 Mar 14
Fourth Quarter/Full Year 2013 Earnings Presentation
12:00am
inflection points
* Financial Overview (in USD at 31-Dec-13 exchange rate) Research and development Total R&D expenses decreased by $5.8 million, to $12.7 … million in 2013 2013 includes $1.7 million one-time reversal of OCS liability “Normalized” R&D decreased by $4.1 million Decrease resulted primarily from
6-K
BLRX
Bioline Rx Ltd
30 Dec 13
Current report (foreign)
12:00am
of Development at several biotechnology companies, the most recent being Thrombotech Ltd. and LycoRed Ltd. In addition, Dr. Aharon has been a partner in R&D Integrative
6-K
EX-99.1
BLRX
Bioline Rx Ltd
5 Mar 15
Current report (foreign)
12:00am
Medical Center
Sheba Medical Center
Hadassah Medical Center
Sourasky Medical Center
Main Pipeline Assets
Main 2014 Achievements
R&D Achievements … % of remaining R&D expenses up to POC (in equity at a premium to market)
– Novartis receives right of first negotiation for full out-license upon clinical POC
6-K
EX-1
BLRX
Bioline Rx Ltd
6 Aug 14
Second Quarter 2014 Earnings Presentation
12:00am
)
Research and development
Total R&D expenses decreased by $5.3 million, to $5.6 million for the six months
ended June 30, 2014
Primarily from
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Nov 14
Third Quarter 2014 Earnings Presentation
12:00am
York in February
Roth Conference in LA in March
Financial Overview
(in USD at 30-Sep-14 exchange rate)
Research and development
Total R&D expenses
6-K
4n4qqbsyyhci6
20 May 14
Current report (foreign)
12:00am
6-K
EX-99
lu979cgx0
23 Dec 14
Current report (foreign)
12:00am
6-K
EX-99
o8xnzvyuo9upwb1acd29
28 Jun 22
BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in
7:14am
20FR12B
EX-4.13
r5ibnuo
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
F-1
EX-10.13
5llmqt0pwk
24 Sep 10
Registration statement (foreign)
12:00am
6-K
EX-99.1
otbx o9p9olqx20e5wv
4 Feb 19
Current report (foreign)
4:30pm
6-K
EX-99
ew8ulrysa5gk6y
24 Dec 14
Current report (foreign)
12:00am
6-K
EX-99
7p10rcy5a 7ivj
5 Apr 12
2012 Annual General Meeting of Shareholders
12:00am
6-K
EX-99
g43 x1xs4co
27 Oct 21
2021 Annual General Meeting of Shareholders
5:05pm
6-K
EX-99
30j6918r zu
10 Jul 13
2013 Annual General Meeting of Shareholders
12:00am
6-K
EX-99
8s9j3vo26ysjrgcwwi
19 Aug 20
2020 Annual General Meeting of Shareholders
4:34pm
6-K
EX-99
wosfp 4ll52
9 Feb 15
2015 Annual General Meeting of Shareholders
12:00am